By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix today announced a definitive agreement to buy eBioscience, a flow cytometry and immunoassay reagent firm, for $330 million in cash.

The deal is expected to provide the Santa Clara, Calif.-based microarray firm with commercial opportunities in post-genomic applications of immunology, oncology, cell biology, stem cell biology, and diagnostics. Affy also said that it will augment its growing molecular diagnostics business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.